Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Abeona Therapeutics Inc's Business Segments
Abeona Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
Product
Total Revenue
$ 11
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product0%
- Single Reportable Segment0%
- License0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 20 | - |
| Single Reportable Segment | $ 20 | - |
| License | - | 0% |
Revenue by Product & Service Category - FY
- Product86.6%
- License0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 9 | 86.6% |
| License | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Product0%
- Single Reportable Segment0%
- License0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 20 | - |
| Single Reportable Segment | $ 20 | - |
| License | - | 0% |
Description of Abeona Therapeutics Inc
Abeona Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing and delivering gene therapies for rare genetic diseases. The company is based in New York City, with additional offices in Cleveland, Ohio, and Dallas, Texas. Abeona was founded in 2013 and has since grown in prominence within the field of genetic medicine.
Abeona's primary mission is to develop innovative gene and cell therapies to address unmet medical needs in debilitating genetic diseases. The company's portfolio includes multiple gene therapy programs that target a range of rare and life-threatening disorders. These disorders primarily affect children and are characterized by significant morbidity and mortality.
One of Abeona's most promising gene therapy programs is aimed at treating rare genetic disease called Sanfilippo syndrome, a genetic disorder that affects the brain and central nervous system. The company's leading product candidate, ABO-102, is a gene therapy designed to deliver a functional copy of the missing SGSH gene to cells in the central nervous system, thereby addressing the underlying cause of the disease. ABO-102 has received Orphan Drug designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
In addition to Sanfilippo syndrome, Abeona is also developing gene therapies for other rare genetic diseases, including Epidermolysis Bullosa (EB) and Batten disease. Epidermolysis Bullosa is a family of rare skin disorders characterized by skin fragility and blistering, while Batten disease is a rare neurodegenerative disorder that primarily affects children. Abeona's gene therapy programs for EB and Batten disease are still in early stages of clinical development.
Abeona's gene therapies are based on adeno-associated viral (AAV) vector technology, which is a safe and efficient method for delivering therapeutic genes to target cells. The company leverages its expertise in AAV gene therapy and molecular genetics to develop novel and effective treatments for rare genetic diseases.
In addition to its gene therapy programs, Abeona also focuses on advanced cell therapy technologies, such as Mesenchymal Stem Cells (MSCs), for the treatment of various diseases. MSCs are a type of adult stem cell that possess regenerative and immunomodulatory properties. Abeona aims to develop MSC-based therapies for conditions like osteoarthritis and multiple sclerosis.
To support its research and development efforts, Abeona has established collaborations and partnerships with various academic institutions, research organizations, and industry leaders. The company has also secured funding through grants and partnerships with government agencies and foundations.
Abeona is committed to conducting rigorous clinical trials and ensuring patient safety in its pursuit of developing effective gene therapies. The company works closely with regulatory authorities to meet the requirements for drug approval and aims to bring its novel therapies to patients in need as quickly and efficiently as possible.
Overall, Abeona Therapeutics is a dynamic biopharmaceutical company focused on developing gene and cell therapies to improve the lives of individuals with rare and life-threatening genetic diseases. With its innovative approaches and dedication to scientific advancement, Abeona is making significant contributions to the field of genetic medicine and has the potential to bring transformative treatments to patients worldwide.
Abeona's primary mission is to develop innovative gene and cell therapies to address unmet medical needs in debilitating genetic diseases. The company's portfolio includes multiple gene therapy programs that target a range of rare and life-threatening disorders. These disorders primarily affect children and are characterized by significant morbidity and mortality.
One of Abeona's most promising gene therapy programs is aimed at treating rare genetic disease called Sanfilippo syndrome, a genetic disorder that affects the brain and central nervous system. The company's leading product candidate, ABO-102, is a gene therapy designed to deliver a functional copy of the missing SGSH gene to cells in the central nervous system, thereby addressing the underlying cause of the disease. ABO-102 has received Orphan Drug designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
In addition to Sanfilippo syndrome, Abeona is also developing gene therapies for other rare genetic diseases, including Epidermolysis Bullosa (EB) and Batten disease. Epidermolysis Bullosa is a family of rare skin disorders characterized by skin fragility and blistering, while Batten disease is a rare neurodegenerative disorder that primarily affects children. Abeona's gene therapy programs for EB and Batten disease are still in early stages of clinical development.
Abeona's gene therapies are based on adeno-associated viral (AAV) vector technology, which is a safe and efficient method for delivering therapeutic genes to target cells. The company leverages its expertise in AAV gene therapy and molecular genetics to develop novel and effective treatments for rare genetic diseases.
In addition to its gene therapy programs, Abeona also focuses on advanced cell therapy technologies, such as Mesenchymal Stem Cells (MSCs), for the treatment of various diseases. MSCs are a type of adult stem cell that possess regenerative and immunomodulatory properties. Abeona aims to develop MSC-based therapies for conditions like osteoarthritis and multiple sclerosis.
To support its research and development efforts, Abeona has established collaborations and partnerships with various academic institutions, research organizations, and industry leaders. The company has also secured funding through grants and partnerships with government agencies and foundations.
Abeona is committed to conducting rigorous clinical trials and ensuring patient safety in its pursuit of developing effective gene therapies. The company works closely with regulatory authorities to meet the requirements for drug approval and aims to bring its novel therapies to patients in need as quickly and efficiently as possible.
Overall, Abeona Therapeutics is a dynamic biopharmaceutical company focused on developing gene and cell therapies to improve the lives of individuals with rare and life-threatening genetic diseases. With its innovative approaches and dedication to scientific advancement, Abeona is making significant contributions to the field of genetic medicine and has the potential to bring transformative treatments to patients worldwide.
Abeona Therapeutics Inc. is a biotechnology company that focuses on the development of gene and cell therapies for the treatment of rare and serious genetic diseases. The company is committed to transforming the lives of patients through innovative therapies that address significant unmet medical needs. Below, I provide a detailed overview of the segments, products, and services offered by Abeona Therapeutics.
Segments
1. Gene Therapy:
- Abeonas gene therapy segment deals with the application of genetic material to treat or prevent diseases. The companys approach often involves introducing corrected copies of defective genes into the patient’s cells. This segment is particularly focused on diseases that currently have limited treatment options.
2. Cell Therapy:
- The cell therapy segment encompasses treatments that involve the infusion of healthy cells into a patient to treat diseases. This can include various types of stem cell therapies that aim to restore normal function to affected tissues.
3. Rare Diseases:
- A key focus area for Abeona is the development of therapies for rare diseases, particularly those that stem from genetic mutations. The company aims to create targeted therapies that address the root cause of these diseases, offering hope for patients with limited alternatives.
Products
1. AAV-CSPG4:
- This is an investigational gene therapy designed for the treatment of certain cancers and neurological diseases. It utilizes adeno-associated virus (AAV) technology to deliver a gene payload that targets CSPG4, a protein associated with tumor development.
2. EB-101:
- EB-101 is an investigational cell therapy specifically designed for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disorder. The product involves the use of genetically modified skin cells to restore production of the collagen type that is deficient in affected patients.
3. AB-201:
- This is another investigational gene therapy targeting Sanfilippo Syndrome, a rare genetic disorder that affects the bodys ability to break down certain sugars. The therapy aims to deliver a functional copy of the gene that is malfunctioning in patients with Sanfilippo Syndrome.
Services
1. Clinical Development Services:
- Abeona offers comprehensive clinical development services to advance its therapies through various phases of clinical trials. This includes preclinical research, clinical study design, regulatory strategy, and patient recruitment efforts.
2. Manufacturing Capabilities:
- The company has developed robust manufacturing capabilities to produce its gene and cell therapies according to Good Manufacturing Practices (GMP). This includes scalable production methods that ensure the purity, potency, and quality of the therapeutic products.
3. Regulatory Affairs:
- Abeona has a dedicated team that navigates the complex regulatory landscape of gene and cell therapy products. This service includes preparing and submitting documentation to regulatory agencies, ensuring compliance with all guidelines, and obtaining necessary approvals for clinical trials and product commercialization.
4. Collaboration and Partnerships:
- Abeona actively seeks collaborations with other biotechnology firms, academic institutions, and research organizations. These partnerships are aimed at leveraging additional expertise and resources to accelerate the development of its therapies and enhance the overall impact of its R&D efforts.
Conclusion
Abeona Therapeutics Inc. is a pioneering company focused on addressing the challenges of rare and complex genetic diseases through advanced gene and cell therapies. With dedicated segments targeting both gene and cell innovations, the company is poised to make significant contributions to the fields of biotechnology and therapeutics, improving the quality of life for individuals suffering from these debilitating conditions. The comprehensive suite of services complements its product offerings, enabling the company to bring its innovative treatments to market effectively.
Segments
1. Gene Therapy:
- Abeonas gene therapy segment deals with the application of genetic material to treat or prevent diseases. The companys approach often involves introducing corrected copies of defective genes into the patient’s cells. This segment is particularly focused on diseases that currently have limited treatment options.
2. Cell Therapy:
- The cell therapy segment encompasses treatments that involve the infusion of healthy cells into a patient to treat diseases. This can include various types of stem cell therapies that aim to restore normal function to affected tissues.
3. Rare Diseases:
- A key focus area for Abeona is the development of therapies for rare diseases, particularly those that stem from genetic mutations. The company aims to create targeted therapies that address the root cause of these diseases, offering hope for patients with limited alternatives.
Products
1. AAV-CSPG4:
- This is an investigational gene therapy designed for the treatment of certain cancers and neurological diseases. It utilizes adeno-associated virus (AAV) technology to deliver a gene payload that targets CSPG4, a protein associated with tumor development.
2. EB-101:
- EB-101 is an investigational cell therapy specifically designed for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disorder. The product involves the use of genetically modified skin cells to restore production of the collagen type that is deficient in affected patients.
3. AB-201:
- This is another investigational gene therapy targeting Sanfilippo Syndrome, a rare genetic disorder that affects the bodys ability to break down certain sugars. The therapy aims to deliver a functional copy of the gene that is malfunctioning in patients with Sanfilippo Syndrome.
Services
1. Clinical Development Services:
- Abeona offers comprehensive clinical development services to advance its therapies through various phases of clinical trials. This includes preclinical research, clinical study design, regulatory strategy, and patient recruitment efforts.
2. Manufacturing Capabilities:
- The company has developed robust manufacturing capabilities to produce its gene and cell therapies according to Good Manufacturing Practices (GMP). This includes scalable production methods that ensure the purity, potency, and quality of the therapeutic products.
3. Regulatory Affairs:
- Abeona has a dedicated team that navigates the complex regulatory landscape of gene and cell therapy products. This service includes preparing and submitting documentation to regulatory agencies, ensuring compliance with all guidelines, and obtaining necessary approvals for clinical trials and product commercialization.
4. Collaboration and Partnerships:
- Abeona actively seeks collaborations with other biotechnology firms, academic institutions, and research organizations. These partnerships are aimed at leveraging additional expertise and resources to accelerate the development of its therapies and enhance the overall impact of its R&D efforts.
Conclusion
Abeona Therapeutics Inc. is a pioneering company focused on addressing the challenges of rare and complex genetic diseases through advanced gene and cell therapies. With dedicated segments targeting both gene and cell innovations, the company is poised to make significant contributions to the fields of biotechnology and therapeutics, improving the quality of life for individuals suffering from these debilitating conditions. The comprehensive suite of services complements its product offerings, enabling the company to bring its innovative treatments to market effectively.